About this Event
Please join us for the Clinical Trials Operations (CTO) Research Forum on Wednesday, December 3, 2025, from 1:00 PM - 2:00 PM PT, where Office of Clinical Trial Activation (OCTA) and Industry Contracts Division (ICD), moderated by the Associate Director of CTO, will present on the topic of 90 Days to Activation: A Case Study and Panel on Partnering with Industry Sponsors.
-
Agenda: A panel from OCTA and ICD, moderated by the Associate Director of Clinical Trials Operations, will review a case study highlighting collaboration with Industry sponsors. They’ll share challenges, key takeaways, and best practices, followed by a Q&A.
-
Audience: UCSF Principal Investigators, study team members, and research staff who do, or might, work on Industry-sponsored research studies, and/or with Industry funders or drug/device providers for non-Industry-sponsored studies.
-
SOCRA Continuing Education (CE) Credit: This presentation is one-hour long and counts for (up to) one CE credit, under the Other Seminars/Conferences for Education or Professional Advancement in Clinical Research category. Attendees who are SOCRA certified and would like a Certificate of Attendance will complete a Zoom request form that will (only) be provided at the Research Forum. Certificates will be emailed within two weeks of the event.
---
UCSF welcomes everyone, including people with disabilities, to participate in clinical research staff trainings. To request a reasonable accommodation, please contact CTO@ucsf.edu as soon as possible.
---
All upcoming and past CTO events can be found here.
A recording along with the meeting materials will be available after the session concludes.
Please email CTO@ucsf.edu if you have any questions.
UCSF promotes the exchange of diverse ideas and perspectives, acknowledging that the views and opinions of our guest speakers on campus are their own and may not reflect the perspective of the University. We embrace free speech in the pursuit of greater understanding, consistent with our obligations as a public university under the First Amendment.